Last $7.36 USD
Change Today -0.02 / -0.27%
Volume 505.1K
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

spectrum pharmaceuticals inc (SPPI) Snapshot

Open
$7.43
Previous Close
$7.38
Day High
$7.46
Day Low
$7.32
52 Week High
01/23/14 - $10.32
52 Week Low
04/15/14 - $6.36
Market Cap
484.0M
Average Volume 10 Days
518.4K
EPS TTM
$-1.24
Shares Outstanding
65.8M
EX-Date
12/18/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRUM PHARMACEUTICALS INC (SPPI)

spectrum pharmaceuticals inc (SPPI) Related Bloomberg News

View More Bloomberg News

spectrum pharmaceuticals inc (SPPI) Related Businessweek News

No Related Businessweek News Found

spectrum pharmaceuticals inc (SPPI) Details

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

226 Employees
Last Reported Date: 03/12/14
Founded in 1987

spectrum pharmaceuticals inc (SPPI) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.8M
President and Chief Operating Officer
Total Annual Compensation: $710.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $462.5K
Chief Medical Officer
Total Annual Compensation: $586.3K
Compensation as of Fiscal Year 2013.

spectrum pharmaceuticals inc (SPPI) Key Developments

Spectrum Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 08:40 AM

Spectrum Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 08:40 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Spectrum Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Spectrum Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $47,990,000 compared to $42,439,000 a year ago. Loss from operations was $4,127,000 compared to $13,287,000 a year ago. Loss before income taxes was $8,062,000 compared to $12,545,000 a year ago. Net loss was $11,539,000 or $0.18 basic and diluted per share compared to $7,812,000 or $0.13 basic and diluted per share a year ago. Non-GAAP product sales & license and contract revenue was $47,990,000 compared to $42,439,000 a year ago. Non-GAAP income from operations was $6,149,000 compared to $1,866,000 a year ago. The company recorded non-GAAP net income of $5,265,000, or $0.08 per diluted share, compared to $1,666,000, or $0.03 per basic and diluted share in the comparable period in 2013. For the nine months period, the company reported total revenues of $134,969,000 compared to $114,338,000 a year ago. Loss from operations was $29,937,000 compared to $32,273,000 a year ago. Loss before income taxes was $40,489,000 compared to $33,011,000 a year ago. Net loss was $42,743,000 or $0.66 basic and diluted per share compared to $22,762,000 or $0.38 basic and diluted per share a year ago. Non-GAAP product sales & license and contract revenue was $134,969,000 compared to $106,730,000 a year ago. Non-GAAP income from operations was $16,504,000 compared to non-GAAP loss from operations of $8,365,000 a year ago. The company recorded non-GAAP net income of $13,668,000, or $0.21 per diluted share, compared to a non-GAAP net loss of $5,990,000, or $0.10 per basic and diluted share in the comparable period in 2013.

Spectrum Pharmaceuticals Mulls Acquisitions

Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI) is seeking acquisitions. Joseph Turgeon, President and Chief Operating Officer of Spectrum Pharmaceuticals said, "Finally this portfolio allows our model of acquisition to continue and thrive. We continue our aggressive business development activities to uncover additional opportunities to move our Company forward. I am confident in our future through this unique and desirable position."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $7.36 USD -0.02

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $2.24 USD 0.00
GlaxoSmithKline SAE £12.94 EGP 0.00
Pfizer Ltd/India 1,701 INR +15.90
Progenics Pharmaceuticals Inc $7.08 USD +0.30
Wyeth Ltd 1,138 INR +0.2001
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit www.sppirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.